biOasis Technologies Ord Shs V.BTI.H

RE:RE:RE:Bioasis marries Midatech! Same sex marriage??

[prophetoffactz]

"POOF says   "....How much can Biodexa raise through potential Neuramedy option exercise and potential deal monitization, J&J option exercise(option expires in about 30 business days), milestone payments from existing deals, and upfront from any new deals(eg. cancer or a second deal with Chiesi)? "

If any of that is coming, they didn't need to sell the company."

BTI merged with Midatech and in Biodexa has full-fledged ambitions to be a therapeutics company like Denali Therapeutics and not just an early-stage licensee of a delivery technology. Biodexa has clinical trial infrastructure already in place and scientific teams. What could a second strategic partnership with Chiesi look like with Biodexa able to be a more meaningful partner in the clinic? What could a cancer partnership look like with Biodexa already having clinical trial infrastructure, clinical trials ongoing, and potential complementary cancer assets? Having xB3 validation from J&J and Chiesi and the capability to advance its own xB3 therapeutics through trials can also be worth something. Does the EGF asset also become an xB3 MS therapeutic shortly to be internally developed as EGF advances in trials? BTI wants to be a more meaningful player in harvesting the value of what it owns and in Biodexa it is a much stronger position to do it in Q1 2023 with the closing of the deal. That's not far away now

Rathjen, "We are very excited by the prospects for this transaction given the evident synergies between Bioasis and Midatech”.
-----------

""....it is very important that Biodexa has high confidence it can secure two years cash and make it to hard data scientific milestones...."

A far better option IMO: BTI could do a financing at 10¢ US for 40m shares, with warrants.  That should be enough cash to wait for a partner or just do a dang Phase I study which would zoom the stock up several bucks.  We'd only be diluted by 50% vs 90% or more with MTP."

If BTI issued 40 million shares with 40 million warrants and there is currently ~120 million fully-diluted shares outstanding that's 67% more shares on a fully-diluted basis. BTI could still be two years from clinical trials with xB3. With Biodexa BTI  in a much stronger position in the next few months as EGF goes to clinic, and potential xB3 partnerships are entered, etc.

The thing is on the outside we can't really appreciate what is coming down the pipe. Rathjen and Saltarelli have chosen this path with all information considered. Meditech and Ladenberg Thalmann are in. Time will tell.  

KayakerBC wrote: POOF says   "....How much can Biodexa raise through potential Neuramedy option exercise and potential deal monitization, J&J option exercise(option expires in about 30 business days), milestone payments from existing deals, and upfront from any new deals(eg. cancer or a second deal with Chiesi)? "

If any of that is coming, they didn't need to sell the company.

"....it is very important that Biodexa has high confidence it can secure two years cash and make it to hard data scientific milestones...."

A far better option IMO: BTI could do a financing at 10¢ US for 40m shares, with warrants.  That should be enough cash to wait for a partner or just do a dang Phase I study which would zoom the stock up several bucks.  We'd only be diluted by 50% vs 90% or more with MTP.